Prior Periods' Financial Statement Revision (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Changes and Error Corrections [Abstract]

Schedule of Correction of Misstatements and Revision on Consolidated Statements

The following tables present the effect of the correction of the misstatements and the resulting revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) as well as the effect of recasting the prior periods for the Life Sciences discontinued operations (see Note 2).

	Three Months Ended September 30, 2019
	As Originally Reported		Adjustment		Discontinued Operations Adjustment		As Revised
Cost of sales (exclusive of depreciation and amortization)	$	160,816	$	258	$	(64,420)	$	96,654
Income (loss) from operations	7,672		(258)		(9,225)		(1,811)
Loss before (provision) benefit for income taxes and share of net income from joint venture	(7,159)		(258)		1,168		(6,249)
Loss from continuing operations	(5,597)		(258)		1,019		(4,836)
Net loss	(5,597)		(258)		—		(5,855)
Foreign currency translation loss	(11,448)		270		—		(11,178)
Comprehensive loss	(17,988)		12		—		(17,976)
Basic loss from continuing operations per common share	$	(0.13)	$	(0.01)	$	0.02	$	(0.12)
Basic net loss per common share	$	(0.13)	$	(0.01)	$	—	$	(0.14)
Diluted loss from continuing operations per common share	$	(0.13)	$	(0.01)	$	0.02	$	(0.12)
Diluted net loss per common share	$	(0.13)	$	(0.01)	$	—	$	(0.14)

	Nine Months Ended September 30, 2019
	As Originally Reported		Adjustment		Discontinued Operations Adjustment		As Revised
Cost of sales (exclusive of depreciation and amortization)	$	485,598	$	1,762	$	(186,694)	$	300,666
Income (loss) from operations	16,371		(1,762)		(22,066)		(7,457)
Loss before provision for income taxes and share of net income from joint venture	(29,704)		(1,762)		14,009		(17,457)
Loss from continuing operations	(30,894)		(1,762)		11,850		(20,806)
Net loss	(30,894)		(1,762)		—		(32,656)
Foreign currency translation loss	(11,620)		266		—		(11,354)
Comprehensive loss	(54,275)		(1,496)		—		(55,771)
Basic loss from continuing operations per common share	$	(0.74)	$	(0.04)	$	0.28	$	(0.50)
Basic net loss per common share	$	(0.74)	$	(0.04)	$	—	$	(0.78)
Diluted loss from continuing operations per common share	$	(0.74)	$	(0.04)	$	0.28	$	(0.50)
Diluted net loss per common share	$	(0.74)	$	(0.04)	$	—	$	(0.78)

The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Changes in Stockholders’ Equity.

	As Originally Reported		Adjustment		As Revised
As of and for the three months ended September 30, 2019
Additional paid-in capital	$	513,268	$	(11,762)	$	501,506
Net loss	(5,597)		(258)		(5,855)
Accumulated deficit	(98,888)		7,690		(91,198)
Foreign currency translation loss	(11,448)		270		(11,178)
Accumulated other comprehensive loss	(55,006)		577		(54,429)
Total stockholders' equity	359,797		(3,495)		356,302
As of and for the nine months ended September 30, 2019
Additional paid-in capital	$	513,268	$	(11,762)	$	501,506
Net loss	(30,894)		(1,762)		(32,656)
Accumulated deficit	(98,888)		7,690		(91,198)
Foreign currency translation loss	(11,620)		266		(11,354)
Accumulated other comprehensive loss	(55,006)		577		(54,429)
Total stockholders' equity	359,797		(3,495)		356,302

The following table presents the effect of the correction of the misstatements on the Condensed Consolidated Statements of Cash Flows.

	Nine Months Ended September 30, 2019
	As Originally Reported		Adjustment		As Revised
Net loss	$	(30,894)	$	(1,762)	$	(32,656)
Changes in operating assets and liabilities, net of acquisitions:
Inventories	(5,794)		969		(4,825)
Other	11,078		793		11,871